Literature DB >> 19474519

Mutation analysis of MEN1, HRPT2, CASR, CDKN1B, and AIP genes in primary hyperparathyroidism patients with features of genetic predisposition.

O Vierimaa1, A Villablanca, A Alimov, M Georgitsi, A Raitila, P Vahteristo, C Larsson, A Ruokonen, E Eloranta, T M L Ebeling, J Ignatius, L A Aaltonen, J Leisti, P I Salmela.   

Abstract

OBJECTIVE: Primary hyperparathyroidism (PHPT), a common endocrine condition, is usually caused by sporadically occurring parathyroid adenoma. A subset of patients carry germline mutations in genes such as MEN1 (multiple endocrine neoplasia type 1), HRPT2 (hyperparathyroidism 2), and CASR (calcium-sensing receptor) predisposing to syndromic forms of PHPT or familial isolated hyperparathyroidism (FIHP). Recently, germline mutations in two novel genes AIP (aryl hydrocarbon receptor-interacting protein) and CDKN1B (cyclin-dependent kinase inhibitor 1B) have been found to be associated with endocrine tumors. The purpose of this study was to evaluate the role of MEN1, HRPT2, CASR, AIP, and CDKN1B genes in PHPT patients with clinical features suggestive of genetic predisposition. PATIENTS AND
DESIGN: Medical records of patients treated for PHPT from 1974 to 2001 at Oulu University Hospital were reviewed. Patients with multiglandular or recurrent/persistent disease, other MEN1- related manifestations, aged 40 yr or younger at onset or with a family history of PHPT/MEN1-related tumor were invited to the study. Twenty patients with previously diagnosed MEN1 were excluded. Participants were interviewed and blood samples obtained for biochemical screening and mutation analysis of MEN1, HRPT2, CASR, AIP, and CDKN1B.
RESULTS: Of the 56 invited patients, 29 took part in the study. One patient was found to carry the c. 1356_1367del12 MEN1 founder mutation. Mutations in other genes were not detected.
CONCLUSIONS: Apart from MEN1, mutations in other genes predisposing to PHPT seem to be rare or non-existing in Northern Finnish PHPT patients. No evidence was found for a role of AIP or CDKN1B in PHPT predisposition.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19474519     DOI: 10.1007/BF03346498

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  41 in total

1.  Familial isolated hyperparathyroidism as a variant of multiple endocrine neoplasia type 1 in a large Danish pedigree.

Authors:  M Kassem; T A Kruse; F K Wong; C Larsson; B T Teh
Journal:  J Clin Endocrinol Metab       Date:  2000-01       Impact factor: 5.958

2.  Screening for MEN1 mutations in patients with atypical endocrine neoplasia.

Authors:  A P Dackiw; G J Cote; J B Fleming; P N Schultz; P Stanford; R Vassilopoulou-Sellin; D B Evans; R F Gagel; J E Lee
Journal:  Surgery       Date:  1999-12       Impact factor: 3.982

Review 3.  Guidelines for diagnosis and therapy of MEN type 1 and type 2.

Authors:  M L Brandi; R F Gagel; A Angeli; J P Bilezikian; P Beck-Peccoz; C Bordi; B Conte-Devolx; A Falchetti; R G Gheri; A Libroia; C J Lips; G Lombardi; M Mannelli; F Pacini; B A Ponder; F Raue; B Skogseid; G Tamburrano; R V Thakker; N W Thompson; P Tomassetti; F Tonelli; S A Wells; S J Marx
Journal:  J Clin Endocrinol Metab       Date:  2001-12       Impact factor: 5.958

4.  HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome.

Authors:  J D Carpten; C M Robbins; A Villablanca; L Forsberg; S Presciuttini; J Bailey-Wilson; W F Simonds; E M Gillanders; A M Kennedy; J D Chen; S K Agarwal; R Sood; M P Jones; T Y Moses; C Haven; D Petillo; P D Leotlela; B Harding; D Cameron; A A Pannett; A Höög; H Heath; L A James-Newton; B Robinson; R J Zarbo; B M Cavaco; W Wassif; N D Perrier; I B Rosen; U Kristoffersson; P D Turnpenny; L-O Farnebo; G M Besser; C E Jackson; H Morreau; J M Trent; R V Thakker; S J Marx; B T Teh; C Larsson; M R Hobbs
Journal:  Nat Genet       Date:  2002-11-18       Impact factor: 38.330

5.  The parathyroid/pituitary variant of multiple endocrine neoplasia type 1 usually has causes other than p27Kip1 mutations.

Authors:  Atsushi Ozawa; Sunita K Agarwal; Carmen M Mateo; A Lee Burns; Terri S Rice; Patricia A Kennedy; Caitlin M Quigley; William F Simonds; Lee S Weinstein; Settara C Chandrasekharappa; Francis S Collins; Allen M Spiegel; Stephen J Marx
Journal:  J Clin Endocrinol Metab       Date:  2007-02-13       Impact factor: 5.958

6.  Autosomal dominant primary hyperparathyroidism and jaw tumor syndrome associated with renal hamartomas and cystic kidney disease: linkage to 1q21-q32 and loss of the wild type allele in renal hamartomas.

Authors:  B T Teh; F Farnebo; U Kristoffersson; B Sundelin; J Cardinal; R Axelson; A Yap; M Epstein; H Heath; D Cameron; C Larsson
Journal:  J Clin Endocrinol Metab       Date:  1996-12       Impact factor: 5.958

7.  Alterations of the MEN1 gene in sporadic parathyroid tumors.

Authors:  F Farnebo; B T Teh; S Kytölä; A Svensson; C Phelan; K Sandelin; N W Thompson; A Höög; G Weber; L O Farnebo; C Larsson
Journal:  J Clin Endocrinol Metab       Date:  1998-08       Impact factor: 5.958

8.  Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.

Authors:  L M Mulligan; J B Kwok; C S Healey; M J Elsdon; C Eng; E Gardner; D R Love; S E Mole; J K Moore; L Papi
Journal:  Nature       Date:  1993-06-03       Impact factor: 49.962

9.  No evidence of somatic aryl hydrocarbon receptor interacting protein mutations in sporadic endocrine neoplasia.

Authors:  A Raitila; M Georgitsi; A Karhu; K Tuppurainen; M J Mäkinen; K Birkenkamp-Demtröder; K Salmenkivi; T F Orntoft; J Arola; V Launonen; P Vahteristo; L A Aaltonen
Journal:  Endocr Relat Cancer       Date:  2007-09       Impact factor: 5.678

10.  Mutations in the human Ca(2+)-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism.

Authors:  M R Pollak; E M Brown; Y H Chou; S C Hebert; S J Marx; B Steinmann; T Levi; C E Seidman; J G Seidman
Journal:  Cell       Date:  1993-12-31       Impact factor: 41.582

View more
  8 in total

1.  Proteomics Analysis of Tissue Samples Reveals Changes in Mitochondrial Protein Levels in Parathyroid Hyperplasia over Adenoma.

Authors:  Gurler Akpinar; Murat Kasap; Nuh Zafer Canturk; Mehin Zulfigarova; Eylül Ece Islek; Sertac Ata Guler; Turgay Simsek; Zeynep Canturk
Journal:  Cancer Genomics Proteomics       Date:  2017 May-Jun       Impact factor: 4.069

Review 2.  Genetics of Hyperparathyroidism, Including Parathyroid Cancer.

Authors:  William F Simonds
Journal:  Endocrinol Metab Clin North Am       Date:  2017-02-23       Impact factor: 4.741

Review 3.  Clinical and molecular genetics of parathyroid neoplasms.

Authors:  John M Sharretts; William F Simonds
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2010-06       Impact factor: 4.690

Review 4.  Hyperparathyroid genes: sequences reveal answers and questions.

Authors:  Stephen J Marx
Journal:  Endocr Pract       Date:  2011 Jul-Aug       Impact factor: 3.443

Review 5.  Familial Hyperparathyroidism.

Authors:  Jenny E Blau; William F Simonds
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-25       Impact factor: 5.555

Review 6.  Clinical and Molecular Genetics of Primary Hyperparathyroidism.

Authors:  William F Simonds
Journal:  Horm Metab Res       Date:  2020-03-30       Impact factor: 2.788

7.  Early Onset Primary Hyperparathyroidism Associated with a Novel Germline Mutation in CDKN1B.

Authors:  Marianne S Elston; Goswin Y Meyer-Rochow; Michael Dray; Michael Swarbrick; John V Conaglen
Journal:  Case Rep Endocrinol       Date:  2015-07-14

Review 8.  A clinical perspective of parathyroid hormone related hypercalcaemia.

Authors:  Chau H Han; Christopher H Fry; Pankaj Sharma; Thang S Han
Journal:  Rev Endocr Metab Disord       Date:  2020-03       Impact factor: 6.514

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.